Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Neurocrine Bioscienc (NQ: NBIX ) 137.67 +3.36 (+2.50%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Neurocrine Bioscienc < Previous 1 2 3 4 5 6 7 8 9 Next > Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued. June 20, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals. Via Chartmill 7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline June 17, 2024 With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. Via InvestorPlace Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock? June 14, 2024 Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? Via Chartmill Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans June 14, 2024 Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. Via Investor's Business Daily Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. June 13, 2024 Investors should take note ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a growth stock that remains attractively priced. Via Chartmill Key Takeaways From Neurocrine Biosciences Analyst Ratings May 28, 2024 Via Benzinga Exploring NASDAQ:NBIX's quality characteristics. May 27, 2024 Reasonable growth and debt and a high ROIC for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). Via Chartmill Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. May 24, 2024 NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating. Via Chartmill In the world of growth stocks, NASDAQ:NBIX shines as a value proposition. May 23, 2024 Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). Via Chartmill Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam May 04, 2024 The market rally appears to be picking up steam. Via Investor's Business Daily A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation May 03, 2024 Earnings season moves into final innings, some fast-moving names led by Disney, Ferrari and Constellation report. Via Investor's Business Daily Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review May 03, 2024 The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. Via Investor's Business Daily Topics Economy Exposures Interest Rates Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive. May 03, 2024 Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). Via Chartmill NASDAQ:NBIX, a strong growth stock, setting up for a breakout. May 02, 2024 Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? Via Chartmill Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences May 01, 2024 Via Benzinga Despite its growth, NASDAQ:NBIX remains within the realm of affordability. May 02, 2024 Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. Via Chartmill PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 May 01, 2024 PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. Via Investor's Business Daily NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024 May 01, 2024 NBIX stock results show that Neurocrine Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win May 01, 2024 The company makes Ingrezza, a treatment for the movement disorder known as tardive dyskinesia. Via Investor's Business Daily Sarepta Therapeutics Stock Shows Improved Technical Strength April 29, 2024 The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. Via Investor's Business Daily Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review April 26, 2024 Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. Via Investor's Business Daily 3 Red-Hot Biotech Rockets Blasting Off in 2024 April 24, 2024 The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits. Via InvestorPlace Topics Economy Exposures Economy Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder April 23, 2024 Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in... Via Benzinga No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win April 23, 2024 The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. Via Investor's Business Daily Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides April 16, 2024 From Sentia Medical Sciences, Inc. Via GlobeNewswire The 5 Stocks Most Sold By Insiders This Year April 16, 2024 Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices. Via MarketBeat Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase. April 11, 2024 Via Chartmill Where Neurocrine Biosciences Stands With Analysts April 10, 2024 Via Benzinga For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. April 10, 2024 Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. Via Chartmill Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag. April 05, 2024 In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals. Via Chartmill < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.